Please assess the completion status of the following clinical trial:

Trial Title: Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Toddlers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Aged 12 to 23 months on the day of the first study visit.~* Born at full term of pregnancy (greater than or equal to \[≥\] 37 weeks) or with a birth weight ≥2.5 kilogram (kg) (5.5 pounds).~* Inform Consent Form (ICF) had been signed and dated by the parent(s) or other legally acceptable representative (and by an independent witness if required by local regulations).~* Participant and parent/legally acceptable representative were able to attend all scheduled visits and to comply with all trial procedures.~* Covered by health insurance where applicable.~Exclusion Criteria:~* Participation at the time of study enrollment (or in the 4 weeks preceding the trial vaccination) or planned participation during the present trial period in another clinical trial investigating a vaccine, drug, medical device, or medical procedure.~* Receipt of any vaccine in the 4 weeks preceding the trial vaccination or planned receipt of any vaccine before the final blood draw except for influenza vaccination, which might be received at least 2 weeks before or after the study vaccine.~* Previous vaccination against meningococcal disease with either the trial vaccine or mono-, or polyvalent polysaccharide or Conjugate meningococcal vaccine containing serogroups A, B, C, W, or Y.~* Receipt of immune globulins, blood, or blood-derived products in the past 3 months.~* Known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy, such as anti-cancer chemotherapy or radiation therapy, within the preceding 6 months; or long-term systemic corticosteroid therapy (≥ 2 milligram \[mg\]/kg/day of prednisone or equivalent for more than 2 consecutive weeks within the past 3 months).~* History of meningococcal infection, confirmed either clinically, serologically, or microbiologically.~* At high risk for meningococcal infection during the trial (i.e., participants with persistent complement deficiency, with anatomic or functional asplenia, or participants travelling to countries with high endemic or epidemic disease).~* Known systemic hypersensitivity to any of the vaccine components, or history of a life-threatening reaction to the vaccines used in the trial or to a vaccine containing any of the same substances.~* Known systemic hypersensitivity to latex.~* Known thrombocytopenia, as reported by the parent/legally acceptable representative.~* Bleeding disorder or receipt of anticoagulants in the 3 weeks preceding inclusion, contraindicating IM vaccination.~* Personal history of Guillain-Barré syndrome.~* Personal history of an Arthus-like reaction after vaccination with a tetanus toxoid-containing vaccine.~* Chronic illness that, in the opinion of the Investigator, was at a stage where it might interfere with trial conduct or completion.~* Moderate or severe acute illness/infection (according to Investigator judgment) on the day of vaccination or febrile illness (temperature ≥38.0 degree Celsius (°C). A prospective participant should not be included in the study until the condition had resolved or the febrile event had subsided.~* Receipt of oral or injectable antibiotic therapy within 72 hours prior to the first blood draw.~* Identified as a natural or adopted child of the Investigator or employee with direct involvement in the proposed study.

- Gender: ALL
- Minimum Age: 12 Months
- Maximum Age: 23 Months
- Healthy Volunteers: t

Study Arms:
- Group 1: MenACYW Conjugate Vaccine (Type: EXPERIMENTAL): Healthy, meningococcal-vaccine naive toddlers aged 12 to 23 months received a single dose of MenACYW Conjugate vaccine.
- Group 2: NIMENRIX® (Type: ACTIVE_COMPARATOR): Healthy, meningococcal-vaccine naive toddlers aged 12 to 23 months received a single dose of NIMENRIX® vaccine.

Based on this trial design, predict the completion outcome and termination type (if applicable).